Analysis of multisite hospital records reveals individuals with recurrent Clostridioides difficile infections face a 105% increased risk of developing colorectal cancer compared to those never infected. Single infections showed no elevated risk, but repeated exposures to C. difficile toxin B created a dose-response relationship with cancer development. The effect appeared stronger in women than men. This finding bridges critical gaps between laboratory evidence showing C. difficile toxins promote colon tumor formation in mice and real-world human health outcomes. The bacterial toxin likely damages intestinal cells repeatedly, creating inflammatory conditions conducive to cancer development over time. However, this preprint awaits peer review and represents observational data that cannot establish direct causation. The hospital-based cohort may also introduce selection bias since these patients likely had underlying health conditions requiring hospitalization. While the 2.05 hazard ratio is substantial, the research requires validation in broader populations. These preliminary findings could eventually inform targeted microbiome therapies and enhanced cancer screening protocols for patients with chronic C. difficile infections, representing an incremental but potentially important advance in understanding gut bacteria's role in cancer development.